Physician profile
Jake Rubenstein
NPI 1063869154
$2,832.17
in general payments reported to CMS, 2019-2025
15 companies · $1,540 in 2025
The $1,540 reported for 2025 was more than what 78% of Surgery providers received nationally (typical 2025 total: $281).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $154 · 2023: $225 · 2024: $913 · 2025: $1,540.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $1,387 · Food and Beverage: $1,266 · Education: $25.97.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $1,386.78 |
| Food and Beverage | $1,265.72 |
| Education | $25.97 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Davol INC. | $1,154.21 | 2023-2025 | Phasix Mesh |
| Abbvie INC. | $802.05 | 2024 | |
| Intuitive Surgical, INC. | $311.27 | 2025 | |
| Novo Nordisk INC | $129.01 | 2024-2025 | Ozempic, Wegovy, Rybelsus |
| Silk Road Medical, INC. | $99.68 | 2022 | |
| Lilly USA, LLC | $87.95 | 2022-2024 | Jardiance, Emgality |
| Astrazeneca Pharmaceuticals Lp | $45.94 | 2024-2025 | Tezspire, Farxiga |
| Integra Lifesciences Corporation | $40.79 | 2023 | Integra, Surgimend, Integra Dermal Regeneration Template |
| Bayer Healthcare Pharmaceuticals INC. | $34.16 | 2023-2024 | |
| Teva Pharmaceuticals USA, INC. | $30.03 | 2022 | |
| Neurocrine Biosciences, INC. | $23.89 | 2025 | |
| Ardelyx, INC. | $21.91 | 2024 | Ibsrela |
| Exact Sciences Corporation | $17.58 | 2023 | Cologuard Collection Kit |
| Kowa Pharmaceuticals America, INC. | $17.17 | 2023 | Seglentis, Livalo |
| Paratek Pharmaceuticals, INC. | $16.53 | 2024 | Nuzyra |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jake Rubenstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.